We use cookies for a better user experience. Read our Privacy Policy

I Agree

Atopic Dermatitis Drugs Market

Atopic Dermatitis Drugs Market (Drug Type: Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Atopic Dermatitis Drugs Market Outlook 2031

  • The global atopic dermatitis drugs market was valued at US$ 6.0 Bn in 2021
  • The global market is projected to advance at a CAGR of 14.7% from 2022 to 2031
  • The global atopic dermatitis drugs market is anticipated to reach more than US$ 29.4 Bn by the end of 2031

Analysts’ Viewpoint on Atopic Dermatitis Drugs Market Scenario

The global atopic dermatitis drugs market is expected to grow at a rapid pace during the forecast period due to the rise in prevalence and incidence of the disease across the globe. Surge in atopic dermatitis cases has increased the need for effective treatment drugs such as cyclosporine and atopic eczema antihistamine. Governments in various developed and developing countries are participating in programs to spread awareness about atopic dermatitis medications. Similarly, development of new drugs for treating atopic dermatitis and increase in clinical trials are boosting the demand for new improved treatments for atopic dermatitis. Thus, the global atopic dermatitis market forecast appears promising due to the increase in investment by companies in the development of new treatment drugs. For instance, Sanofi and Pfizer have introduced various drugs for the treatment of atopic dermatitis. These drugs have received the U.S. FDA approval.

Atopic Dermatitis Drugs Market

Atopic Dermatitis Drugs Market Introduction

Atopic dermatitis, also known as eczema, is a condition that affects the skin and causes itchiness, dryness, and inflammation. The condition can be chronic and tends to flare and spread sometimes. Atopic dermatitis drugs, including atopic eczema steroids, are used to treat eczema and reduce itchiness and other conditions caused by atopic dermatitis. The global atopic dermatitis drugs market size is projected to grow at a rapid pace during the forecast period owing to the rise in investment in research & development activities and novel pipeline drugs.

Request a sample to get extensive insights into the Atopic Dermatitis Drugs Market

Increase in Incidence of Atopic Dermatitis Driving Global Market

Dermatological disorders differ across the globe based on geographic location, climatic conditions, socioeconomic status, lifestyle, age, gender, heredity, and personal habits. According to the World Health Organization (WHO), more than 900 million people were affected with skin diseases in 2017, and the five common conditions, including atopic dermatitis, accounted for around 80% of the skin disorders. High prevalence and substantial rise in incidence rate of atopic dermatitis across the globe is the key factor driving the atopic dermatitis drugs market. Atopic dermatitis affects 15% to 20% children and 1% to 3% adults across the world per year. New approvals and commercialization of novel therapeutic drugs under clinical trial studies are projected to propel the global atopic dermatitis market size during the forecast period.

Rise in Demand for Biologics Propelling Global Market

Usage of biologic drugs in dermatology has changed the treatment procedure of dermatological disorders, especially atopic dermatitis. Leading biopharmaceutical companies are investing significantly in biologic product development, merger & acquisitions, and strategic collaborations. Atopic dermatitis has shown positive response to biologics, which has improved the overall quality of life. Hence, overall demand for biologic drugs for atopic dermatitis has increased. This trend is likely to continue in the next few years. Just one biologic product has been approved for the treatment of atopic dermatitis to date. Many more are in phase II clinical trials and are likely to receive approvals in the near future.

Request a custom report on Atopic Dermatitis Drugs Market

Inhibition of Causative Inflammatory Response to Fuel Biologics Segment

In terms of drug type, the biologics segment dominated the global atopic dermatitis drugs market, with around 76% share in 2021. The trend is projected to continue during the forecast period. The segment is anticipated to be driven by the rise in prevalence of atopic dermatitis, as biologics inhibit the inflammatory response that is responsible for the development of the disease. According to the Dermatology Therapeutics Area Working Group, global prevalence rate of atopic dermatitis stands at 8% to 15% in children.

Retail Pharmacies Segment Lead Global Market

In terms of distribution channel, the global atopic dermatitis drugs market has been segmented into hospital pharmacies, retail pharmacies and online pharmacies. The retail pharmacies segment held major share of around 65% in 2021. Growth of the segment can be ascribed to the increase in purchasing power of patients and surge in the number of retail pharmacies.

Regional Outlook of Global Atopic Dermatitis Drugs Market

North America accounted for the largest share of around 46% of the global atopic dermatitis drugs market in 2021. This can be ascribed to large patient pool in the region that requires efficient and new therapies.

Europe held around 30% share of the global market in 2021. The market in the region is expected to grow at a faster pace from 2022 to 2031 due to the increase in focus on the development of health care infrastructure by governments and rise in demand for affordable, effective therapeutics among the significant patient population.

Asia Pacific accounted for larger market share than Latin America and Middle East & Africa in 2021. However, the market in Latin America is expected to grow at a faster pace than that in Middle East & Africa.

Analysis of Key Players in Global Atopic Dermatitis Drugs Market

The atopic dermatitis drugs market report concludes with the company profiles section, which includes key information about major players in the global atopic dermatitis drugs market. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the global atopic dermatitis drugs market. Prominent players in the atopic dermatitis drugs market are Mylan N.V., Pfizer, Inc., LEO Pharma A/S, Sanofi, Novartis AG, Bausch Health, and Teva Pharmaceutical Industries Ltd.

Key Developments in Global Atopic Dermatitis Drugs Market

  • In June 2022, the U.S. Food and Drug Administration (FDA) approved the first biologic Dupixent (dupilumab) for treatment of children aged six months to five years with moderate to severe dermatitis, when the disease is not adequately controlled with topical therapies
  • In January 2022, Pfizer announced that the U.S. FDA had approved its CIBINQO (abrocitinib) for treating adults with moderate to severe atopic dermatitis. CIBINQO (abrocitinib) is an oral drug that contains Janus kinase 1 (JAK1) inhibitors.

Each of these players has been profiled in the atopic dermatitis drugs market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Atopic Dermatitis Drugs Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 6.0 Bn

Market Forecast Value in 2031

More than US$ 29.4 Bn

Growth Rate (CAGR) for 2022-2031

14.7%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Type
    • Corticosteroids
    • PDE4 Inhibitors
    • Biologics
    • Skin Barrier Emollients
    • CNI Immunosuppressants
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Mylan N.V.
  • Pfizer, Inc.
  • LEO Pharma A/S
  • Sanofi
  • Novartis AG
  • Bausch Health
  • Teva Pharmaceutical Industries Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Atopic Dermatitis Drugs Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global atopic dermatitis drugs market in 2021?

The global atopic dermatitis drugs market was valued at US$ 6.0 Bn in 2021

How big will be the global atopic dermatitis drugs market in 2031?

The global atopic dermatitis drugs market is projected to reach more than US$ 29.4 Bn by 2031

What will be the CAGR of the global atopic dermatitis drugs market during the forecast period (2022–2031)?

The global atopic dermatitis drugs market is anticipated to grow at a CAGR of 14.7% from 2022 to 2031

What is the market share of the leading segment of the global atopic dermatitis drugs market?

The biologics segment held around 76% share of the global atopic dermatitis drugs market in 2021

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global atopic dermatitis drugs market during the forecast period.

Who are the prominent players in the global atopic dermatitis drugs market?

Prominent players in the global atopic dermatitis drugs market are Mylan N.V., Pfizer, Inc., LEO Pharma A/S, Sanofi, Novartis AG, Bausch Health, and Teva Pharmaceutical Industries Ltd.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Atopic Dermatitis Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Type Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Atopic Dermatitis Drugs Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Disease Epidemiology

    5.2. Pipeline Analysis

    5.3. Key Industry Events

    5.4. COVID-19 Impact Analysis

6. Global Atopic Dermatitis Drugs Market Analysis and Forecast, by Drug Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Type, 2017–2031

        6.3.1. Corticosteroids

        6.3.2. PDE4 Inhibitors

        6.3.3. Biologics

        6.3.4. Skin Barrier Emollients

        6.3.5. CNI Immunosuppressants

        6.3.6. Others

    6.4. Market Attractiveness Analysis, by Drug Type

7. Global Atopic Dermatitis Drugs Market Analysis and Forecast, by Distribution Channel

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Distribution Channel, 2017–2031

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Atopic Dermatitis Drugs Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Region

9. North America Atopic Dermatitis Drugs Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Drug Type, 2017–2031

        9.2.1. Corticosteroids

        9.2.2. PDE4 Inhibitors

        9.2.3. Biologics

        9.2.4. Skin Barrier Emollients

        9.2.5. CNI Immunosuppressants

        9.2.6. Others

    9.3. Market Value Forecast, by Distribution Channel, 2017–2031

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. Market Value Forecast, by Country, 2017–2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Drug Type

        9.5.2. By Distribution Channel

        9.5.3. By Country

10. Europe Atopic Dermatitis Drugs Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Type, 2017–2031

        10.2.1. Corticosteroids

        10.2.2. PDE4 Inhibitors

        10.2.3. Biologics

        10.2.4. Skin Barrier Emollients

        10.2.5. CNI Immunosuppressants

        10.2.6. Others

    10.3. Market Value Forecast, by Distribution Channel, 2017–2031

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Pharmacies

    10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Drug Type

        10.5.2. By Distribution Channel

        10.5.3. By Country/Sub-region

11. Asia Pacific Atopic Dermatitis Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Type, 2017–2031

        11.2.1. Corticosteroids

        11.2.2. PDE4 Inhibitors

        11.2.3. Biologics

        11.2.4. Skin Barrier Emollients

        11.2.5. CNI Immunosuppressants

        11.2.6. Others

    11.3. Market Value Forecast, by Distribution Channel, 2017–2031

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Online Pharmacies

    11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis

        11.5.1. By Drug Type

        11.5.2. By Distribution Channel

        11.5.3. By Country/Sub-region

12. Latin America Atopic Dermatitis Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Type, 2017–2031

        12.2.1. Corticosteroids

        12.2.2. PDE4 Inhibitors

        12.2.3. Biologics

        12.2.4. Skin Barrier Emollients

        12.2.5. CNI Immunosuppressants

        12.2.6. Others

    12.3. Market Value Forecast, by Distribution Channel, 2017–2031

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Online Pharmacies

    12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis

        12.5.1. By Drug Type

        12.5.2. By Distribution Channel

        12.5.3. By Country/Sub-region

13. Middle East & Africa Atopic Dermatitis Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Type, 2017–2031

        13.2.1. Corticosteroids

        13.2.2. PDE4 Inhibitors

        13.2.3. Biologics

        13.2.4. Skin Barrier Emollients

        13.2.5. CNI Immunosuppressants

        13.2.6. Others

    13.3. Market Value Forecast, by Distribution Channel, 2017–2031

        13.3.1. Hospital Pharmacies

        13.3.2. Retail Pharmacies

        13.3.3. Online Pharmacies

    13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis

        13.5.1. By Drug Type

        13.5.2. By Distribution Channel

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by tier and size of companies)

    14.2. Market Share Analysis, by Company, 2021

    14.3. Company Profiles

        14.3.1. Mylan N.V.

            14.3.1.1. Company Description

            14.3.1.2. Business Overview

            14.3.1.3. Financial Overview

            14.3.1.4. Strategic Overview

            14.3.1.5. SWOT Analysis

        14.3.2. Pfizer, Inc.

            14.3.2.1. Company Description

            14.3.2.2. Business Overview

            14.3.2.3. Financial Overview

            14.3.2.4. Strategic Overview

            14.3.2.5. SWOT Analysis

        14.3.3. LEO Pharma A/S

            14.3.3.1. Company Description

            14.3.3.2. Business Overview

            14.3.3.3. Financial Overview

            14.3.3.4. Strategic Overview

            14.3.3.5. SWOT Analysis

        14.3.4. Sanofi

            14.3.4.1. Company Description

            14.3.4.2. Business Overview

            14.3.4.3. Financial Overview

            14.3.4.4. Strategic Overview

            14.3.4.5. SWOT Analysis

        14.3.5. Novartis AG

            14.3.5.1. Company Description

            14.3.5.2. Business Overview

            14.3.5.3. Financial Overview

            14.3.5.4. Strategic Overview

            14.3.5.5. SWOT Analysis

        14.3.6. Bausch Health

            14.3.6.1. Company Description

            14.3.6.2. Business Overview

            14.3.6.3. Financial Overview

            14.3.6.4. Strategic Overview

            14.3.6.5. SWOT Analysis

        14.3.7. Teva Pharmaceutical Industries Ltd.

            14.3.7.1. Company Description

            14.3.7.2. Business Overview

            14.3.7.3. Financial Overview

            14.3.7.4. Strategic Overview

            14.3.7.5. SWOT Analysis

List of Tables

Table 01: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 02: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031

Table 03: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 04: North America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 05: North America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 06: North America Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 07: Europe Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 08: Europe Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 09: Europe Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 10: Asia Pacific Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 11: Asia Pacific Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 12: Asia Pacific Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Latin America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Latin America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 15: Latin America Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 16: Middle East and Africa Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Middle East and Africa Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 18: Middle East and Africa Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031

Figure 03: Global Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 04: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2031

Figure 05: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by PDE4 Inhibitors, 2017–2031

Figure 06: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Biologics, 2017–2031

Figure 07: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Skin Barrier Emollients, 2017–2031

Figure 08: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, CNI Immunosuppressants, 2017–2031

Figure 09: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Others, 2017–2031

Figure 10: Global Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 11: Global Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 12: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Hospital Pharmacies, 2017–2031

Figure 13: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Retail Pharmacies, 2017–2031

Figure 14: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Online Pharmacies, 2017–2031

Figure 15: Global Atopic Dermatitis Drugs Market Value Share Analysis, by Region, 2021 and 2031

Figure 16: Global Atopic Dermatitis Drugs Market Attractiveness Analysis, by Region, 2022–2031

Figure 17: North America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 18: North America Atopic Dermatitis Drugs Market Value Share Analysis, by Country, 2021 and 2031

Figure 19: North America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country, 2022–2031

Figure 20: North America Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031

Figure 21: North America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 22: North America Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 23: North America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 24: Europe Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 25: Europe Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 26: Europe Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 27: Europe Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031

Figure 28: Europe Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 29: Europe Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 30: Europe Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 31: Asia Pacific Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 32: Asia Pacific Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 33: Asia Pacific Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 34: Asia Pacific Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031

Figure 35: Asia Pacific Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 36: Asia Pacific Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 37: Asia Pacific Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 38: Latin America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 39: Latin America Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 40: Latin America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 41: Latin America Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031

Figure 42: Latin America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 43: Latin America Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 44: Latin America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 45: Middle East and Africa Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 46: Middle East and Africa Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 47: Middle East and Africa Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 48: Middle East and Africa Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031

Figure 49: Middle East and Africa Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 50: Middle East and Africa Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 51: Middle East and Africa Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

881

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved